We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+3.46%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$343M
AUM Growth
-$50.3M
(-13%)
Cap. Flow
-$56.3M
Cap. Flow
% of AUM
-16.41%
Top 10 Holdings %
Top 10 Hldgs %
78.35%
Holding
286
New
92
Increased
41
Reduced
68
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$1.84M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$1.31M |
| 3 |
GXO Logistics
GXO
|
+$1.26M |
| 4 |
Aurora
AUR
|
+$1.11M |
| 5 |
Puma Biotechnology
PBYI
|
+$1.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$30.4M |
| 2 |
iShares MBS ETF
MBB
|
+$29.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$1.86M |
| 4 |
Azenta
AZTA
|
+$1.53M |
| 5 |
Synopsys
SNPS
|
+$1.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 24.12% |
| 2 | Healthcare | 12.62% |
| 3 | Financials | 1.65% |
| 4 | Technology | 1.41% |
| 5 | Industrials | 1.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Collegium Pharmaceutical
COLL
$1.16B
| $1.13M | 0.33% |
60,500
+23,500
| +64% | +$458K |
|
|
27
Aurora
AUR
$12B
| $1.13M | 0.33% |
+100,000
| New | +$1.11M |
|
|
MFA
28
MFA Financial
MFA
$942M
| $1.11M | 0.32% |
61,109
+7,500
| +14% | +$137K |
|
29
Arcutis Biotherapeutics
ARQT
$3.52B
| $1.09M | 0.32% |
52,500
+17,000
| +48% | +$338K |
|
|
RVNC
30
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.06M | 0.31% |
65,000
+58,500
| +900% | +$975K |
|
31
BioXcel Therapeutics
BTAI
$27.2M
| $1.02M | 0.3% |
3,125
+937
| +43% | +$402K |
|
32
Aclaris Therapeutics
ACRS
$786M
| $989K | 0.29% |
68,000
+17,000
| +33% | +$258K |
|
|
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
| $962K | 0.28% |
137,000
+89,500
| +188% | +$936K |
|
|
COOP
34
DELISTED
Mr. Cooper
COOP
| $948K | 0.28% |
22,794
| – | – |
|
35
AeroVironment
AVAV
$7.24B
| $930K | 0.27% |
15,000
| – | – |
|
|
SAFE
36
Safehold
SAFE
$1.18B
| $920K | 0.27% |
7,317
+1,096
| +18% | +$134K |
|
37
Karyopharm Therapeutics
KPTI
$157M
| $900K | 0.26% |
9,333
+266
| +3% | +$26.5K |
|
38
Procept Biorobotics
PRCT
$1.08B
| $875K | 0.26% |
35,000
+15,000
| +75% | +$555K |
|
|
ONIT
39
Onity Group
ONIT
$340M
| $858K | 0.25% |
21,477
| – | – |
|
40
AEye
LIDR
$57M
| $847K | 0.25% |
5,833
+2,500
| +75% | +$385K |
|
41
BioMarin Pharmaceuticals
BMRN
$11.5B
| $839K | 0.24% |
9,500
+1,500
| +19% | +$124K |
|
42
PennyMac Financial
PFSI
$4.33B
| $816K | 0.24% |
11,699
| – | – |
|
|
TPTX
43
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $811K | 0.24% |
+17,000
| New | +$760K |
|
44
Insmed
INSM
$23.6B
| $776K | 0.23% |
28,500
| – | – |
|
45
AdaptHealth
AHCO
$1.5B
| $770K | 0.22% |
31,500
+3,500
| +13% | +$82.2K |
|
46
Microbot Medical
MBOT
$122M
| $750K | 0.22% |
100,000
| – | – |
|
47
Bristol-Myers Squibb
BMY
$124B
| $748K | 0.22% |
12,000
+11,290
| +1,590% | +$662K |
|
|
TCRR
48
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $704K | 0.21% |
151,000
+38,000
| +34% | +$238K |
|
|
ITOS
49
DELISTED
iTeos Therapeutics
ITOS
| $698K | 0.2% |
+15,000
| New | +$499K |
|
50
PTC Therapeutics
PTCT
$6.49B
| $697K | 0.2% |
17,500
+5,000
| +40% | +$191K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, AlphaCentric Advisors held 286 positions worth $343M, down 13% from $393M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
AlphaCentric Advisors withdrew a net $56.3M in Q4 2021, closing 66 positions and reducing 68 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $1.86M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 24% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Jazz Pharmaceuticals worth $1.27M.
- AlphaCentric Advisors's largest Q4 2021 buy was Jazz Pharmaceuticals: 10,000 shares worth $1.27M.
- AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2021, an estimated $1.84M increase.
- AlphaCentric Advisors's biggest Q4 2021 reduction was Vanguard Mortgage-Backed Securities ETF, cutting an estimated $30.4M.
- AlphaCentric Advisors fully exited Vertex Pharmaceuticals in Q4 2021, selling an estimated $1.86M.
- AlphaCentric Advisors's ten largest holdings make up 78% of its $343M portfolio in Q4 2021.
- AlphaCentric Advisors opened 92 new positions and closed 66 in Q4 2021.
- AlphaCentric Advisors's portfolio value fell 13% quarter-over-quarter to $343M.
Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.